On August 7th, Gelonghui reported that Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Fuan Pharmaceutical Group Qing Yu Tang Pharmaceutical Co., Ltd. (referred to as 'Qing Yu Tang'), recently received the drug supplement application approval notice issued by the National Drug Administration. After review, the injection of ceftizoxime sodium ('specification 1.0g') passed the consistency evaluation of quality and efficacy of generic drugs.
The injection of ceftizoxime sodium is an anti-infective drug mainly used for lower respiratory tract infections, urinary tract infections, abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections, pneumococcal or influenza meningitis and uncomplicated gonorrhea caused by susceptible bacteria. Qing Yu Tang's 0.5g and 1.0g specifications for this product have both passed the consistency evaluation. According to the National Drug Administration's relevant information platform, as of now, three companies (including Qing Yu Tang) have passed the consistency evaluation or been deemed to have passed the consistency evaluation for this drug.